The Effect of Vitamin B12, Magnesium and Vitamin D in COVID-19 among Geriatric Patients
et al., International Journal of Pharmaceutical and Clinical Research, 14:5
, The Effect of Vitamin B12, Magnesium and Vitamin D in COVID-19 among Geriatric Patients, International Journal of Pharmaceutical and Clinical Research, 14:5
Prospective study of 30 patients treated with vitamin D, magnesium, and vitamin B12, and 25 control patients, showing shorter hospitalization and lower oxygen and ICU requirements with treatment. Cholecalciferol 1000IU, magnesium oxide 150mg, vitamin B12 500μg.
|
risk of ICU admission, 86.8% lower, RR 0.13, p = 0.09, treatment 0 of 30 (0.0%), control 3 of 25 (12.0%), NNT 8.3, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
|
|
hospitalization time, 38.5% lower, relative time 0.62, p < 0.001, treatment mean 11.2 (±2.8) n=30, control mean 18.2 (±1.21) n=25.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Valecha et al., 26 Apr 2022, prospective, India, peer-reviewed, 1 author, average treatment delay 3.7 days, this trial uses multiple treatments in the treatment arm (combined with magnesium and vitamin B12) - results of individual treatments may vary.
Loading..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.